The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease
Open accessAbstract
BACKGROUND AND AIMS: The intestinal microbiota play a pivotal role in the inflammation associated with Crohn's disease through their interaction with the mucosal immune system. Some bifidobacteria species are immunoregulatory and induce increased dendritic cell interleukin 10 (IL-10) release in vitro. Fructo-oligosaccharides (FOS) increase faecal and mucosal bifidobacteria in healthy volunteers. The aim of this study was to assess the effect of FOS administration on disease activity, bifidobacteria concentrations, and mucosal dendritic cell function in patients with moderately active Crohn's disease. PATIENTS AND METHODS: Ten patients with active ileocolonic Crohn's disease received 15 g of FOS for three weeks. Disease activity was measured using the Harvey Bradshaw index. Faecal and mucosal bifidobacteria were quantified by fluorescence in situ hybridisation, and mucosal dendritic cell IL-10 and Toll-like receptor (TLR) expression were assessed by flow cytometry of dissociated rectal biopsies. RESULTS: FOS induced a significant reduction in the Harvey Bradshaw index from 9.8 (SD 3.1) to 6.9 (3.4) (p<0.01). There was a significant increase in faecal bifidobacteria concentration from 8.8 (0.9) log(10) to 9.4 (0.9) log(10) cells/g dry faeces (p<0.001). The percentage of IL-10 positive dendritic cells increased from 30 (12)% to 53 (10)% (p=0.06). Finally, the percentage of dendritic cells expressing TLR2 and TLR4 increased from 1.7 (1.7)% to 36.8 (15.9)% (p=0.08) and from 3.6 (3.6)% to 75.4 (3.4)% (p<0.001), respectively. CONCLUSIONS: FOS supplementation increases faecal bifidobacteria concentrations and modifies mucosal dendritic cell function. This novel therapeutic strategy appears to decrease Crohn's disease activity in a small open label trial and therefore warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an open label trial of fructo-oligosaccharide in CD showed promise,79”
From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [79]
In the citing paper
“Additionally, prebiotic use has been shown to improve mucosal dendritic cell function associated with TLR2 activity [62], and increase the expression of glucagon-like peptide 2, associated with GI barrier regulation [59].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
Amann, R., Binder, B. J., Olson, R. J., Chisholm, S. W., Devereux, R., & Stahl, D. A. (1990) · Applied and Environmental Microbiology · doi:10.1128/aem.56.6.1919-1925.1990 · Cited by 4,049
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Harvey, R. F., & Bradshaw, J. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92767-1 · Cited by 2,974
Rescigno, M., Urbano, M., Valzasina, B., Francolini, M., Rotta, G., Bonasio, R., Granucci, F., Kraehenbuhl, J.-P., & Ricciardi‐Castagnoli, P. (2001) · Nature Immunology · doi:10.1038/86373 · Cited by 2,554
Kadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964
Induction of Protective IgA by Intestinal Dendritic Cells Carrying Commensal Bacteria
Macpherson, A. J., & Uhr, T. (2004) · Science · doi:10.1126/science.1091334 · Cited by 1,584
Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin
Gibson, G. R., Beatty, E. R., Wang, X., & Cummings, J. H. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90192-2 · Cited by 1,529
Sellon, R. K., Tonkonogy, S., Schultz, M., Dieleman, L. A., Grenther, W., Balish, E., Rennick, D. M., & Sartor, R. B. (1998) · Infection and Immunity · doi:10.1128/iai.66.11.5224-5231.1998 · Cited by 1,483
Mucosal flora in inflammatory bowel disease
Swidsinski, A. V., Ladhoff, A., Pernthaler, A., Swidsinski, S., Loening-Baucke, V. A., Ortner, M., Weber, J., Hoffmann, U., Schreiber, S., Dietel, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.30294 · Cited by 1,344
Manz, W., Amann, R., Ludwig, W., Vancanneyt, M., & SCHLEIFER, K. H. (1996) · Microbiology · doi:10.1099/13500872-142-5-1097 · Cited by 1,176
Research works printed but not linked: 1
- Stagg AJ, Kamm MA, Knight SC. Intestinal dendritic cells increase T cell expression of alpha4 beta7 integrin. Eur J Immunol 2002;32:1445-54.
Cited by
Sorted by citations
Effects of probiotics, prebiotics, and synbiotics on human health
Markowiak, P., & Śliżewska, K. (2017) · Nutrients · doi:10.3390/nu9091021 · Cited by 2,401
The gut microbiota and host health: a new clinical frontier
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A., Hirschfield, G. M., Hold, G., Quraishi, M. N., Kinross, J., Smidt, H., Tuohy, K. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309990 · Cited by 2,302
“…no clinically relevant evidence base for the use of probiotics in CD and in terms of prebiotics, although an open label trial of fructo-oligosacchar-ide in CD showed promise, 79 and a subsequent randomised placebo-controlled trial of fructo-oligosaccharide did not support any clinical bene fi t. 80”
BackgroundPrebiotic effects: metabolic and health benefits
Roberfroid, M. B., Gibson, G. R., Hoyles, L., McCartney, A. L., Rastall, R. A., Rowland, I. R., Wolvers, D. A. W., Watzl, B., Szajewska, H., Stahl, B., et al. (2010) · British Journal Of Nutrition · doi:10.1017/s0007114510003363 · Cited by 2,170
Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications
Davani-Davari, D., Negahdaripour, M., Karimzadeh, I., Seifan, M., Mohkam, M., Masoumi, S. J., Berenjian, A., & Ghasemi, Y. (2019) · Foods · doi:10.3390/foods8030092 · Cited by 1,848
Probiotics, prebiotics and synbiotics- a review
Pandey, K. R., Naik, S. R., & Vakil, B. V. (2015) · Journal of Food Science and Technology · doi:10.1007/s13197-015-1921-1 · Cited by 1,350
Metadata
- Authors
- Lindsay, J. O.
- Affiliations
- Royal London Hospital (GB)
- Corresponding author
- Lindsay, J O
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2006-03-01
- Volume
- 55
- Issue
- 3
- Pages
- 348-355
- ISSN
- 0017-5749 (ISSN-L)
- PMC
- PMC1856087
- OpenAlex
- W2164571061
- Cited by
- 471
- References
- 55
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 33 · 2023: 19 · 2022: 35 · 2021: 26 · 2020: 32 · 2019: 20 · 2018: 21 · 2017: 18 · 2016: 21 · 2015: 18 · 2014: 26 · 2013: 21 · 2012: 22
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gut (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Nursing › Nutrition and Dietetics › Microbial Metabolites in Food Biotechnology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- fructooligosaccharides, Crohn's disease, Bifidobacterium, dendritic cells, IL-10, TLR2, TLR4, gut microbiota, mucosal immunity, disease activity, prebiotics, rectal mucosa
- MeSH terms
- Adult, Bifidobacterium, Crohn Disease, Dendritic Cells, Feces, Female, Humans, Intestinal Mucosa, Male, Middle Aged, Oligosaccharides, Patient Compliance, Severity of Illness Index, Immunity, Mucosal, Toll-Like Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
